新一代VMAT2抑制剂诱发帕金森症。
New generation VMAT2 inhibitors induced parkinsonism.
作者信息
Vasireddy Rani Priyanka, Sokola Brent, Guduru Zain
机构信息
University of Kentucky Medical Center, United States.
出版信息
Clin Park Relat Disord. 2020 Nov 7;3:100078. doi: 10.1016/j.prdoa.2020.100078. eCollection 2020.
Abstract
•Drug induced parkinsonism caused by valbenazine and deutetrabenazine.•Possible side effects of VMAT-2 inhibitors.•Valbenazine and deutetrabenazine can unmask underlying Parkinson's Disease.
摘要
• 由丙戊嗪和氘代丁苯那嗪引起的药物性帕金森综合征。
• VMAT-2抑制剂可能的副作用。
• 丙戊嗪和氘代丁苯那嗪可使潜在的帕金森病显现出来。
相似文献
1
New generation VMAT2 inhibitors induced parkinsonism.新一代VMAT2抑制剂诱发帕金森症。
Clin Park Relat Disord. 2020 Nov 7;3:100078. doi: 10.1016/j.prdoa.2020.100078. eCollection 2020.
2
Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.迟发性运动障碍：将囊泡单胺转运体 2（VMAT2）抑制剂置于临床视角。
Expert Rev Neurother. 2018 Apr;18(4):323-332. doi: 10.1080/14737175.2018.1455504. Epub 2018 Apr 2.
3
Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.Valbenazine 和 deutetrabenazine：用于迟发性运动障碍的囊泡单胺转运体 2 抑制剂。
Am J Health Syst Pharm. 2020 Jan 24;77(3):167-174. doi: 10.1093/ajhp/zxz299.
4
Risk of VMAT2 inhibitors on suicidality and parkinsonism: report utilizing the United States Food and Drug Administration adverse event reporting system.VMAT2抑制剂引发自杀倾向和帕金森症的风险：利用美国食品药品监督管理局不良事件报告系统的报告
Int Clin Psychopharmacol. 2025 May 1;40(3):176-181. doi: 10.1097/YIC.0000000000000553. Epub 2024 May 11.
5
Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.迟发性运动障碍的治疗：概述及重点关注囊泡单胺转运体 2 抑制剂。
Drugs. 2018 Apr;78(5):525-541. doi: 10.1007/s40265-018-0874-x.
6
VMAT2 Inhibitors in Neuropsychiatric Disorders.VMAT2 抑制剂在神经精神疾病中的应用。
CNS Drugs. 2018 Dec;32(12):1131-1144. doi: 10.1007/s40263-018-0580-y.
7
VMAT2 inhibitors for the treatment of hyperkinetic movement disorders.VMAT2 抑制剂治疗多动性运动障碍。
Pharmacol Ther. 2020 Aug;212:107580. doi: 10.1016/j.pharmthera.2020.107580. Epub 2020 May 23.
8
A systematic review on treatment of tardive dyskinesia with valbenazine and deutetrabenazine.一项关于用缬苯那嗪和氘代丁苯那嗪治疗迟发性运动障碍的系统评价。
Ther Adv Psychopharmacol. 2019 May 20;9:2045125319847882. doi: 10.1177/2045125319847882. eCollection 2019.
9
Dopamine depleters in the treatment of hyperkinetic movement disorders.多巴胺耗竭剂在治疗多动性运动障碍中的应用。
Expert Opin Pharmacother. 2016 Dec;17(18):2461-2470. doi: 10.1080/14656566.2016.1258063.
10
VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.用于迟发性运动障碍的VMAT2抑制剂——实践意义
J Pharm Pract. 2019 Aug;32(4):450-457. doi: 10.1177/0897190018756512. Epub 2018 Feb 18.
引用本文的文献
1
Electroconvulsive therapy for depression and oral dyskinesia in a patient who developed parkinsonism induced by valbenazine.电休克治疗用于一名因使用丙戊嗪诱发帕金森症的患者的抑郁症和口部运动障碍。
PCN Rep. 2025 Jun 10;4(2):e70135. doi: 10.1002/pcn5.70135. eCollection 2025 Jun.
2
The Role of Ultrasound in the Evaluation of Tardive Dyskinesia: A Case Series.超声在迟发性运动障碍评估中的作用：病例系列
Tremor Other Hyperkinet Mov (N Y). 2025 Jan 17;15:3. doi: 10.5334/tohm.966. eCollection 2025.
3
HDAC4/5 Inhibitor, LMK-235 Improves Animal Voluntary Movement in MPTP-Induced Parkinson's Disease Model.HDAC4/5抑制剂LMK-235改善MPTP诱导的帕金森病模型动物的自主运动。
Pharmacol Res Perspect. 2025 Feb;13(1):e70057. doi: 10.1002/prp2.70057.
4
Tardive Dyskinesia With Chorea-Ballism Improved by Valbenazine: A Case Report.丙戊嗪改善迟发性运动障碍伴舞蹈症-手足徐动症：一例报告
Cureus. 2024 Feb 22;16(2):e54666. doi: 10.7759/cureus.54666. eCollection 2024 Feb.
5
Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.比较研究二氢苯丁氮酮和戊苯那嗪作为 VMAT2 抑制剂治疗迟发性运动障碍的疗效：系统综述。
Tremor Other Hyperkinet Mov (N Y). 2024 Mar 13;14:13. doi: 10.5334/tohm.842. eCollection 2024.
本文引用的文献
1
Valbenazine-induced parkinsonism.缬苯那嗪诱发的帕金森综合征。
Parkinsonism Relat Disord. 2020 Jan;70:13-14. doi: 10.1016/j.parkreldis.2019.11.021. Epub 2019 Nov 25.
2
Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management.抗精神病药物相关运动障碍：药物性帕金森综合征与迟发性运动障碍——病理生理学和临床管理的关键差异
Neurol Ther. 2018 Dec;7(2):233-248. doi: 10.1007/s40120-018-0105-0. Epub 2018 Jul 19.
3
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.氘代丁苯那嗪治疗迟发性运动障碍患者不自主运动的研究（AIM-TD）：一项双盲、随机、安慰剂对照的3期试验。
Lancet Psychiatry. 2017 Aug;4(8):595-604. doi: 10.1016/S2215-0366(17)30236-5. Epub 2017 Jun 28.
4
KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.KINECT 3 试验：坎非丁治疗迟发性运动障碍的 3 期随机、双盲、安慰剂对照试验
Am J Psychiatry. 2017 May 1;174(5):476-484. doi: 10.1176/appi.ajp.2017.16091037. Epub 2017 Mar 21.
5
Drug-induced movement disorders.药物性运动障碍
Neurol Clin. 2015 Feb;33(1):153-74. doi: 10.1016/j.ncl.2014.09.011.
Zotero 插件